You are here

C3 glomerulopathy

Novartis' Fabhalta is first FDA-approved therapy for rare disease C3G

Pharmaphorum

Fri, 03/21/25 - 11:19 am

C3 glomerulopathy

Novartis eyes year-end filing in US for Fabhalta in C3G

Pharmaphorum

Mon, 10/28/24 - 10:17 am

C3 glomerulopathy

Novartis unveils promising Fabhalta data for C3 glomerulopathy indication

Medical Marketing and Media

Tue, 12/12/23 - 09:56 am

clinical trials

C3 glomerulopathy